Litchfield Caroline
Known title: EVP & CFOCIK: 0001854928
Associated companies
Transaction History
| MRK | ▼ Sell | Tax Withholding | 1,938 | $213K | 4/29/2026 | View on chart |
| MRK | ▲ Buy | Option Exercise | 3,935 | $433K | 4/29/2026 | View on chart |
| MRK | ▲ Buy | Option Exercise | 41,997 | $2.2M | 2/4/2026 | View on chart |
| MRK | ▼ Sell | Open Market | 41,997 | $5.0M | 2/4/2026 | View on chart |
| MRK | ▲ Buy | Grant | 15,852 | $1.7M | 1/26/2026 | View on chart |
| MRK | ▲ Buy | Grant | 23,432 | $2.3M | 1/27/2025 | View on chart |
| MRK | ▲ Buy | Option Exercise | 38,291 | $2.2M | 2/14/2024 | View on chart |
| MRK | ▼ Sell | Open Market | 38,291 | $4.8M | 2/14/2024 | View on chart |
| MRK | ▲ Buy | Grant | 19,208 | $2.3M | 1/22/2024 | View on chart |
| MRK | ▲ Buy | Option Exercise | 866 | $100K | 5/1/2023 | View on chart |
| MRK | ▼ Sell | Tax Withholding | 427 | $49K | 5/1/2023 | View on chart |
| MRK | ▲ Buy | Grant | 2,656 | $292K | 1/23/2023 | View on chart |
| MRK | ▲ Buy | Option Exercise | 773 | $68K | 5/3/2022 | View on chart |
| MRK | ▼ Sell | Tax Withholding | 373 | $33K | 5/3/2022 | View on chart |
| MRK | ▲ Buy | Option Exercise | 866 | $77K | 5/1/2022 | View on chart |
| MRK | ▼ Sell | Tax Withholding | 427 | $38K | 5/1/2022 | View on chart |
| MRK | ▲ Buy | Grant | 2,429 | $179K | 2/24/2022 | View on chart |
| MRK | ▲ Buy | Option Exercise | 22,683 | $0 | 11/4/2021 | View on chart |
| MRK | ▼ Sell | Open Market | 18,335 | $1.7M | 11/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Merck Stock Rally Draws Attention to Valuation Concerns
Recent market commentary highlights a renewed confidence in Merck, with analysts debating whether the current rally has priced in too much optimism. While comparisons with peers like AbbVie and Bristol Myers Squibb focus on dividend yields and value, the primary discussion centers on the sustainability of Merck's recent price movement. The stock's high trailing P/E ratio of 112.6 provides context for these valuation concerns, suggesting that investors are closely monitoring if the current momentum can be sustained.
Merck Stock Rally Draws Attention to Valuation Concerns. Recent market commentary highlights a renewed confidence in Merck, with analysts debating whether the current rally has priced in too much optimism. While comparisons with peers like AbbVie and Bristol Myers Squibb focus on dividend yields and value, the primary discussion centers on the sustainability of Merck's recent price movement. The stock's high trailing P/E ratio of 112.6 provides context for these valuation concerns, suggesting that investors are closely monitoring if the current momentum can be sustained.